Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas

Phaeochromocytomas and paragangliomas (PPGLs) are neural-crest-derived tumours of the sympathetic or parasympathetic nervous system that are often inherited and are genetically heterogeneous. Genetic testing is recommended for patients with these tumours and for family members of patients with hereditary forms of PPGLs. Due to the large number of susceptibility genes implicated in the diagnosis of inherited PPGLs, next-generation sequencing (NGS) technology is ideally suited for carrying out genetic screening of these individuals. This Consensus Statement, formulated by a study group comprised of experts in the field, proposes specific recommendations for the use of diagnostic NGS in hereditary PPGLs. In brief, the study group recommends target gene panels for screening of germ line DNA, technical adaptations to address different modes of disease transmission, orthogonal validation of NGS findings, standardized classification of variant pathogenicity and uniform reporting of the findings. The use of supplementary assays, to aid in the interpretation of the results, and sequencing of tumour DNA, for identification of somatic mutations, is encouraged. In addition, the study group launches an initiative to develop a gene-centric curated database of PPGL variants, with annual re-evaluation of variants of unknown significance by an expert group for purposes of reclassification and clinical guidance.

[1]  Richard Bourgon,et al.  High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing , 2014, Clinical Cancer Research.

[2]  M. Heymann,et al.  Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[3]  G. Perilongo,et al.  Somatic mosaicism in von Hippel‐Lindau disease , 2000, Human mutation.

[4]  P. Rustin,et al.  Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.

[5]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[6]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[7]  A. Vénisse,et al.  The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  H. Neumann,et al.  Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing Analysis , 2015, International journal of endocrinology.

[9]  Functional and in silico assessment of MAX variants of unknown significance , 2015, Journal of Molecular Medicine.

[10]  J. Shendure,et al.  Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.

[11]  W. Dinjens,et al.  Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis. , 2016, The Journal of clinical endocrinology and metabolism.

[12]  E. Korpershoek,et al.  Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients , 2015, Journal of Medical Genetics.

[13]  W. Grody,et al.  Quality control in molecular genetic testing , 2001, Nature Reviews Genetics.

[14]  M. Urioste,et al.  MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma , 2012, Clinical Cancer Research.

[15]  K. Pacak,et al.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts , 2016, Journal of internal medicine.

[16]  Jefferey Chen,et al.  Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing. , 2016, The Journal of molecular diagnostics : JMD.

[17]  R. Tothill,et al.  The genomic landscape of phaeochromocytoma , 2015, The Journal of pathology.

[18]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[19]  W. Dinjens,et al.  SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  C. Larsson,et al.  Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. , 2012, Human molecular genetics.

[21]  S. Srikantan,et al.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. , 2013, Endocrine-related cancer.

[22]  T. Dwight,et al.  Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[23]  L. Aaltonen,et al.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. , 2004, American journal of human genetics.

[24]  T. Poeppel,et al.  A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A. , 2016, The Journal of clinical endocrinology and metabolism.

[25]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[26]  C. Eng,et al.  Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. , 2004, The Journal of clinical endocrinology and metabolism.

[27]  E. Baudin,et al.  Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  E. Letouzé,et al.  Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. , 2012, Human molecular genetics.

[29]  C. Stratakis,et al.  Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? , 2012, Endocrine-related cancer.

[30]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[31]  R. Letón,et al.  Rationalization of Genetic Testing in Patients with Apparently Sporadic Pheochromocytoma/Paraganglioma , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[32]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[33]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[34]  C. Stratakis,et al.  Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications12 , 2015, Neoplasia.

[35]  M. Korbonits,et al.  A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[36]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[37]  P. Bénit,et al.  SDHA is a tumor suppressor gene causing paraganglioma. , 2010, Human molecular genetics.

[38]  Elspeth A. Bruford,et al.  Genenames.org: the HGNC resources in 2015 , 2014, Nucleic Acids Res..

[39]  A. Vénisse,et al.  Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. , 2011, Human molecular genetics.

[40]  A. Hernigou,et al.  A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. , 2011, European journal of endocrinology.

[41]  R. Greenberg,et al.  Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas , 2014, Nature Communications.

[42]  M. Greenblatt.  Sequence Variants of Uncertain Significance: What to Do When Genetic Test Results Are Not Definitive. , 2015, Surgical oncology clinics of North America.

[43]  Aurélie Morin,et al.  Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas , 2015, Nature Communications.

[44]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[45]  S. Richard,et al.  Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[47]  P. Hellman,et al.  Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma , 2013, Endocrine connections.

[48]  U. Shankavaram,et al.  Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia , 2014, Journal of Molecular Medicine.

[49]  P. Meltzer,et al.  Recurrent epimutation of SDHC in gastrointestinal stromal tumors , 2014, Science Translational Medicine.

[50]  E. van Marck,et al.  An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. , 2009, The Lancet. Oncology.

[51]  E. Dequeker,et al.  Genetic testing and quality control in diagnostic laboratories , 2000, Nature Genetics.

[52]  S. Gruber,et al.  Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. , 2010, JAMA.

[53]  Yufeng Shen,et al.  Whole‐Exome sequencing identifies novel LEPR mutations in individuals with severe early onset obesity , 2014, Obesity.

[54]  C. Larsson,et al.  Frequent EPAS1 / HIF2 a exons 9 and 12 mutations in non-familial pheochromocytoma , 2014 .

[55]  C. Eng,et al.  Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients , 2009, Clinical Cancer Research.

[56]  P. Hellman,et al.  Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. , 2013, The Journal of clinical endocrinology and metabolism.

[57]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[58]  Robert M. Deiters.  Organization for Economic Co-Operation and Development (OECD). , 1968 .

[59]  Nicola Wolstenholme,et al.  What's in a Name? A Coordinated Approach toward the Correct Use of a Uniform Nomenclature to Improve Patient Reports and Databases , 2016, Human mutation.

[60]  F. Faucz,et al.  Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria. , 2015, Endocrine-related cancer.

[61]  R. Aguiar,et al.  Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas , 2015, Clinical Cancer Research.

[62]  E. Letouzé,et al.  SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma , 2014, International journal of cancer.

[63]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[64]  M. Schatz.  Biological data sciences in genome research , 2015, Genome research.

[65]  M. Papotti,et al.  H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. , 2014, The Journal of clinical endocrinology and metabolism.

[66]  B. Robinson,et al.  15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5 , 2015, Endocrine-related cancer.

[67]  C. Stratakis,et al.  Familial gastrointestinal stromal tumors and germ-line mutations. , 2007, The New England journal of medicine.

[68]  P. Dahia.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.

[69]  S. Salzberg,et al.  Repetitive DNA and next-generation sequencing: computational challenges and solutions , 2011, Nature Reviews Genetics.

[70]  B. Klink,et al.  Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. , 2016, The Journal of clinical endocrinology and metabolism.

[71]  A. Tischler,et al.  New syndrome of paraganglioma and somatostatinoma associated with polycythemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Bénit,et al.  In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma , 2015, Clinical Cancer Research.

[73]  A. Tischler,et al.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T) , 2015, Modern Pathology.

[74]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[75]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[76]  G. Pita,et al.  Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. , 2013, Human molecular genetics.

[77]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[78]  E. Baudin,et al.  Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics , 2012, Hormone and Metabolic Research.

[79]  E. Maher,et al.  15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. , 2015, Endocrine-related cancer.

[80]  Laurence Amar,et al.  SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.

[81]  Fiona Douglas,et al.  Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.

[82]  P. Rustin,et al.  The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. , 2001, American journal of human genetics.

[83]  Jenny Welander,et al.  Whole‐exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene , 2015, Genes, chromosomes & cancer.

[84]  C. Cremers,et al.  SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. , 2010, The Lancet. Oncology.

[85]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[86]  Juan F. García,et al.  Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. , 2015, Journal of the National Cancer Institute.

[87]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[88]  E. Lucci-Cordisco,et al.  Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. , 2012, Endocrine-related cancer.

[89]  M. Sibony,et al.  SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. , 2015, The Journal of clinical endocrinology and metabolism.

[90]  J. Blangero,et al.  Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility , 2014, Endocrine-related cancer.

[91]  A. Vénisse,et al.  A Decade (2001–2010) of Genetic Testing for Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.

[92]  Josephine T. Daub,et al.  267 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic Variation , 2016, Molecular biology and evolution.

[93]  S. Srikantan,et al.  The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. , 2014, Human molecular genetics.

[94]  Borut Peterlin,et al.  Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) , 2013, European Journal of Human Genetics.

[95]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[96]  B. Dickson,et al.  Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association , 2015, Virchows Archiv.

[97]  P. Dahia,et al.  Integrity of the pheochromocytoma susceptibility TMEM127 gene in patients with pediatric malignancies. , 2015, Endocrine-related cancer.

[98]  Mario Cannataro,et al.  Bioinformatics and Microarray Data Analysis on the Cloud. , 2016, Methods in molecular biology.

[99]  P. Meltzer,et al.  SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. , 2015, Journal of the National Cancer Institute.

[100]  P. Söderkvist,et al.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. , 2011, Endocrine-related cancer.

[101]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[102]  Glenn A. Maston,et al.  A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.

[103]  E. Maher.  Genetics of Familial Renal Cancers , 2010, Nephron Experimental Nephrology.

[104]  B. Martínez-Delgado,et al.  Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot? , 2006, Genes, chromosomes & cancer.

[105]  Yiping Shen,et al.  Monozygotic twins discordant for neurofibromatosis 1 , 2010, American journal of medical genetics. Part A.

[106]  A. Gimenez-Roqueplo,et al.  HIF2A mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[107]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[108]  P. Rustin,et al.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. , 2003, Cancer research.

[109]  M. Marshall,et al.  Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas , 2014, Clinical endocrinology.

[110]  Stephen J. Salipante,et al.  Performance Comparison of Illumina and Ion Torrent Next-Generation Sequencing Platforms for 16S rRNA-Based Bacterial Community Profiling , 2014, Applied and Environmental Microbiology.

[111]  Jenny Welander,et al.  Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. , 2014, The Journal of clinical endocrinology and metabolism.

[112]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[113]  Emma M. Rath,et al.  Structural and functional consequences of succinate dehydrogenase subunit B mutations. , 2015, Endocrine-related cancer.

[114]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[115]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[116]  Bruce E. Bowdish,et al.  Reporting genomic secondary findings: ACMG members weigh in , 2014, Genetics in Medicine.

[117]  L. Mulligan,et al.  High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. , 2010, The Journal of clinical endocrinology and metabolism.

[118]  M. Fraga,et al.  DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers , 2015, Clinical Cancer Research.

[119]  F. Galateau-Sallé,et al.  PHD2 mutation and congenital erythrocytosis with paraganglioma. , 2008, The New England journal of medicine.

[120]  A. Ligon,et al.  A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors , 2008, Human Genetics.

[121]  W. Dinjens,et al.  Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. , 2010, The Journal of clinical endocrinology and metabolism.

[122]  A. Knudson,et al.  Mutation and cancer: neuroblastoma and pheochromocytoma. , 1972, American journal of human genetics.

[123]  G. Arnaldi,et al.  Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.